Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Duchenne Muscular Dystrophy (DMD) Therapeutics Market From 2025 To 2029?
In recent times, the market size for duchenne muscular dystrophy (DMD) therapeutics has seen a significant expansion. The market is projected to surge from $11.95 billion in 2024 to $16.38 billion in 2025, with a compound annual growth rate (CAGR) of 37.0%. Factors contributing to the stellar growth in the historic period include the rising incidence of duchenne muscular dystrophy, elevated awareness about its treatment, increased expenditure on healthcare, and government-led initiatives.
In the forthcoming years, a substantial upswing is expected in the market size of Duchenne Muscular Dystrophy (DMD) therapeutics, which is projected to reach $47.74 billion by 2029, driven by a CAGR of 30.7%. Multiple factors can be credited for this expansion over the forecast period, including the increase in funding for DMD treatments, the practice of combined therapies, the rise of biomarkers, and a growing amount of screening programs for DMD. Furthermore, the prediction period will also see several significant trends like innovative DMD treatments, the creation of targeted therapies, the launch of new medications and therapies, inventive disease-altering therapies, and ongoing drug developments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
What are the Fundamental Drivers and Innovations Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
The uptick in clinical trials is projected to drive Duchenne muscular dystrophy (DMD) therapeutics market expansion. These are research projects undertaken on human subjects to ascertain the potential benefits, safety, and efficiency of newly developed medical interventions or drugs. The rise in clinical trials centred on Duchenne muscular dystrophy therapies underscores the relentless pursuit of research, innovation, and a broad spectrum of therapeutic options. Collectively, these factors are likely to improve patient prospects, entice investments and fast-track the progress and availability of effective treatments for Duchenne Muscular Dystrophy (DMD). For instance, in August 2023, as per data from Clinicaltrials.Gov, an offshoot of The National Institutes Of Health (NIH), a U.S. government body in charge of directing and backing medical research, the tally of registered clinical trials escalated to 464,218, a rise from 399,496 in 2021. This increase occurred across all 50 states of the U.S. and in 221 different countries. Additionally, it was disclosed that 142,700 studies, or 31% of the total, were registered in the U.S., and 248,310 studies, or 53% of all total studies, were documented in non-U.S. locations. Consequently, the upswing in the count of clinical trials is set to push the Duchenne muscular dystrophy (DMD) therapeutics market’s growth.
How Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmented?
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12916&type=smp
Which Regions Are Driving the Next Phase of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth?
North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Trends Are Shaping the Future of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
Prominent firms in the Duchenne muscular dystrophy (DMD) therapeutics market are leveraging advanced technologies to increase the effectiveness and availability of DMD treatments in order to maintain their market prominence. In example, Bit Bio Ltd., a synthetic biology corporation based in the UK, unveiled disease model products in July 2023 to expedite DMD treatment advancements. These disease models, titled ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes imbued with genetically engineered deletions in the dystrophin-producing gene. Bit. Bio’s models, derived from induced pluripotent stem cells (iPSCs), deliver a reliable and expandable source of human cells for research, tackling hurdles related to variability and primary cell sourcing. The models expedite DMD treatments’ development by offering insights into disease processes and potential treatment options, potentially fast-tracking researchers’ efforts to find effective DMD treatments.
View the full report here:
How Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Defined and What Are Its Core Parameters?
Duchenne muscular dystrophy (DMD) therapeutics refers to the various medical treatments and interventions aimed at managing and alleviating the symptoms of duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle weakness and degeneration. These therapeutic approaches are designed to slow disease progression, improve muscle function and enhance the overall quality of life for individuals with duchenne muscular dystrophy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12916
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model